PharmaMar has announced today the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of the world’s leading oncology markets.

PharmaMar (MCE: PHM) has announced today the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of the world’s leading oncology markets.
As Luis Mora, Managing Director at PharmaMar´s Oncology Business Unit, explains “the opening of this affiliate is part of our growth strategy in certain Europeancountries; this allows us to offer a better attention to our customersthroughour own teams. From Austria we can operate directly in Eastern European countries such as Poland and theCzech Republic.”
With this new affiliate in Austria, PharmaMar now has a presence, with its own structure, in eight European countries. The other subsidiaries are located in Italy, Germany, France, Switzerland, Spain, the United Kingdom andBelgium consolidating the Company’s business and distribution model.
The incidence of cancer in Austria
According to GLOBOCAN^[i] data, in 2012 41,100 new cases of cancer were detected in Austria. It is estimated that the risk of suffering cancer before the age of 75 is 30% in men and 22% in women. Prostrate, breast and colorectal cancer are the most frequent types of tumor in Austria.
About PharmaMar
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS^® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com
i. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx # [http://globocan.iarc.fr/Pages/fact_sheets_population.aspx ]
Media Relations (Paula Fernández – +34-638-79-62-15) and Investor Relations (+34-914444500)
SOURCE PharmaMar